Zeitschrift für Biochemie und Zellbiologie

Abstrakt

Solid Lipid Nanoparticles of Guggul Lipid after Pulmonary Delivery

Lao Toe

Using guggul lipid as the primary lipid component, diclofenac sodium-loaded solid lipid nanoparticles (SLNs) were created and then their physical characteristics, permeation profiles, and anti-inflammatory action were examined. The SLNs were made utilising the melt-emulsion sonication/low temperature-solidification process, and they were then evaluated for physical characteristics, in vitro drug release, and accelerated stability experiments before being formed into gel. Regarding drug absorption in vivo and ex vivo as well as anti-inflammatory effectiveness, various gels were compared with a commercial emulgel (CEG) and a simple carbopol gel containing drug (CG). Maximum physical parameters kept the SLNs steady. The two particles with the highest in vitro drug release were GMS nanoparticle 1 (GMN-1) and stearic acid nanoparticle 1 (SAN-1). The receptor fluid drug concentration of Guggul lipid nanoparticle gel 3 (GLNG-3) was 104.68 times higher than that of CEG. With regard to CG, GLNG-3's enhancement ratio was 39.43. At 4 hours, GLNG-3 revealed to be around 8.12 times greater than CEG. AUC for GLNG-3 was 15.28 times greater than AUC for CEG. In the first hour, edoema inhibition in GLNG-3 reached 69.47%. The features of SLN are controlled by the primary lipid component's physicochemical characteristics. The physicochemical characteristics and stability of SLN derived from guggul lipid were good. Additionally, it demonstrated a favourable penetration profile as well as a regulated drug release profile. The primary goal of this research was to investigate the biodistribution of amikacin solid lipid nanoparticles (SLNs) after pulmonary delivery to raise its concentration in the lungs for treating cystic fibrosis lung infections and to offer a fresh approach to amikacin therapeutic application. In order to achieve this goal, 99mTclabeled amikacin was loaded in cholesterol SLNs. Following in vitro optimization, the appropriate SLNs and free drug were delivered through the pulmonary and routes to male rats, and quality and biodistribution experiments were carried out. The outcomings demonstrated that pulmonary delivery of SLNs of amikacin by microsprayer caused higher drug concentration in lungs than kidneys while i.v. administration of free medication generated reverse conditions.